US 12,064,120 B2
Systems and methods for left ventricular unloading in biologic therapy or vectored gene therapy
Roger J Hajjar, Tenafly, NJ (US); Kiyotake Ishikawa, Fort Lee, NJ (US); Jerald Wayne Curran, Danvers, MA (US); and Noam Josephy, Danvers, MA (US)
Assigned to ABIOMED, INC., Danvers, MA (US)
Filed by ABIOMED, Inc., Danvers, MA (US)
Filed on Mar. 27, 2020, as Appl. No. 16/832,924.
Claims priority of provisional application 62/959,333, filed on Jan. 10, 2020.
Claims priority of provisional application 62/826,444, filed on Mar. 29, 2019.
Prior Publication US 2020/0305888 A1, Oct. 1, 2020
Int. Cl. A61B 17/12 (2006.01); A61K 48/00 (2006.01); A61M 60/17 (2021.01); A61M 60/237 (2021.01); A61M 60/833 (2021.01); C12N 15/85 (2006.01)
CPC A61B 17/12122 (2013.01) [A61B 17/12136 (2013.01); A61K 48/005 (2013.01); A61K 48/0075 (2013.01); A61M 60/17 (2021.01); A61M 60/237 (2021.01); A61M 60/833 (2021.01); C12N 15/85 (2013.01); A61M 2202/206 (2013.01)] 6 Claims
OG exemplary drawing
 
1. A method of upregulating gene expression in a patient's myocardium, comprising the steps of:
placing a balloon in a coronary artery of a patient;
inflating the balloon for a first period to temporarily block blood flow within the coronary artery during the first period;
placing a blood pump into a heart of the patient and positioning the blood pump across an aortic valve of the heart;
operating the blood pump in the heart of the patient during a second period; and
during the first period, injecting a gene therapy vector within the coronary artery at a location distal of the inflated balloon, and
deflating the inflated balloon after the first period to restore blood flow within the coronary artery, wherein the first period occurs during the second period and the first period has a duration that does not cause permanent ischemia in cells of the patient's myocardium.